ライフサイエンスコーパス: MMR vaccine

1 and estimates of school level uptake of the MMR vaccine.

2 0.01) after the introduction of the two-dose MMR vaccine.

3 students had received at least two doses of MMR vaccine.

4 tolerability of this early administration of MMR vaccine.

5 ling data to support a routine third dose of MMR vaccine.

6 harges for rubella is most likely due to the MMR vaccine.

7 ed (P=.01) immune responses after 2 doses of MMR vaccine.

8 children with egg allergy should receive the MMR vaccine.

9 ible to receive the measles, mumps, rubella (MMR) vaccine.

10 ecommended 2 doses of mumps-measles-rubella (MMR) vaccine.

11 nd/or receiving the measles, mumps, rubella (MMR) vaccine.

12 dents with 2 doses of measles-mumps-rubella (MMR) vaccine.

13 and 2 doses of measles, mumps, and rubella (MMR) vaccine.

14 a third dose of the measles, mumps, rubella (MMR) vaccine.

15 d immunization with Measles, Mumps, Rubella (MMR) vaccine.

16 MMR vaccine 2 receipt 28 days or more after MMR vaccine 1 and by 84 months of age, and (3) receipt o

17 Primary outcomes were (1) timely MMR vaccine 1 receipt by 16 months of age, (2) timely MM

18 Students who had received a second dose of MMR vaccine 13 years or more before the outbreak had an

19 ne 1 receipt by 16 months of age, (2) timely MMR vaccine 2 receipt 28 days or more after MMR vaccine

20 andidate is based on three components of the MMR vaccine, a measles virus Edmonston and the two mumps

21 We identified 131 reports of MMR vaccine administered to a pregnant woman; the majori

22 ive patients, 60 patients received 1 dose of MMR vaccine and 14 patients received 1 dose of varicella

23 do not support a causal association between MMR vaccine and autism.

24 ), Polio, Measles, Rubella, Mumps, trivalent MMR vaccine and Haemophilus influenza type B (HiB) vacci

25 age 18 months, compared with risk following MMR vaccine and vaccine uptake for 2-dose MCV and single

26 ansplant recipients received 1 to 3 doses of MMR vaccine and/or 1 to 3 doses of VZV vaccine.

27 ed link between the measles, mumps, rubella (MMR) vaccine and autism continues to cause concern and c

28 g no link between the measles-mumps-rubella (MMR) vaccine and autism spectrum disorders (ASD), belief

29 wo doses of the measles, mumps, and rubella (MMR) vaccine; and proportions with medical or personal-b

30 Two doses of measles, mumps, and rubella (MMR) vaccine are 97% effective against measles, but wani

31 ar-old Finnish children vaccinated once with MMR vaccine at 11-19 months of age.

32 Febrile seizures occurred after dose 1 of MMR vaccine at a known low increased risk (RI, 2.71; 95%

33 ers considered 6612 (16%) to be eligible for MMR vaccine at the time of pretravel consultation.

34 in historical cohorts recommended to receive MMR vaccine before school entry, and on-time vaccination

35 After an MMR vaccine booster dose, we noted a seroconversion of 7

36 accine and 8 to 14 days after the receipt of MMR vaccine, but these risks do not appear to be associa

37 he known effects of the measles component of MMR vaccine-but not in the 15- to 35-day period (relativ

38 12 receive 2 doses of measles-mumps-rubella (MMR) vaccine by 2001.

39 a, health officials implemented a widespread MMR vaccine campaign.

40 Severe illness by MMR vaccines can be caused by inborn errors of type I an

41 suggested that measles, mumps, and rubella (MMR) vaccine causes autism.

42 Measles-mumps-rubella (MMR) vaccines containing the Urabe strain of mumps were

43 From 2001 through 2008, national 1-dose MMR vaccine coverage among children 19-35 months of age

44 A 5% decline in MMR vaccine coverage in the United States would result i

45 hs in municipalities with routine first-dose MMR vaccine coverage of <90%.

46 For infants who received an early MMR vaccine dose (n = 962), we asked for information abo

47 omali descent had significantly lower timely MMR vaccine dose 1 coverage at all time points (overall

48 Timely MMR vaccine dose 1 coverage remained unchanged (66 143 o

49 Timely MMR vaccine dose 2 coverage increased modestly (44 210 o

50 status and years since receipt of the second MMR vaccine dose.

51 nely, the first measles, mumps, and rubella (MMR) vaccine dose is given at 14 months of age in the Ne

52 Receipt of valid MMR vaccine doses per Centers for Disease Control and Pr

53 d that early introduction of a third dose of MMR vaccine during a mumps outbreak can be effective in

54 evel costs of measles outbreak, encompassing MMR vaccine expenses, treatment costs, and productivity

55 of adults aged >/=19 years who received the MMR vaccine from 1 January 2003 to 31 July 2013.

56 Measles-mumps-rubella (MMR) vaccine (given as either MMR or measles-mumps-rubel

57 the participants (80%) received their second MMR vaccine >=10 years prior to study participation.

58 Students who had received a third dose of MMR vaccine had a lower risk of mumps than did those who

59 TP) vaccine and measles, mumps, and rubella (MMR) vaccine has been associated with adverse neurologic

60 The combined measles, mumps, and rubella (MMR) vaccine has been successfully administered for >20

61 t the campaign to administer a third dose of MMR vaccine improved mumps outbreak control and that wan

62 period, VAERS received 3175 US reports after MMR vaccine in adults.

63 to infer the effectiveness of the third-dose MMR vaccine in preventing mumps cases by analyzing the m

64 on real-life effectiveness of the third-dose MMR vaccine in preventing mumps.

65 g introduction of the measles-mumps-rubella (MMR) vaccine in 1988.

66 ction of the two-dose measles-mumps-rubella (MMR) vaccine in 1996, and the implementation of the Newb

67 vaccine as a combined measles-mumps-rubella (MMR) vaccine in 1999 and the implementation of measles i

68 e safety of the measles, mumps, and rubella (MMR) vaccine in adults.

69 f a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown.

70 lliamsburg who received at least one dose of MMR vaccine increased from 79.5% to 91.1% among children

71 hildren who present with mild illnesses with MMR vaccine is a safe and efficacious practice.

72 nt with genesis before one year of age, when MMR vaccine is typically administered.

73 Because the measles-mumps-rubella (MMR) vaccine is an attenuated live virus vaccine, we als

74 The measles-mumps-rubella (MMR) vaccine is effective in eliciting a good antibody r

75 stigate whether measles, mumps, and rubella (MMR) vaccine may be causally associated with autism.

76 dates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jery

77 x, age, age at receipt of the second dose of MMR vaccine (MMR2), or time since receipt of MMR2 (P = .

78 verage of all schoolchildren with 2 doses of MMR vaccine, most states are well on their way toward th

79 wed by MMRV vaccine, 97 (24.8%) had received MMR vaccine only, and 16 (4.1%) had received neither vac

80 the measles-mumps-rubella (MMR) vaccine, the MMR vaccine only, and the expanded 2008 schedule.

81 trial, 39 healthy adults received either the MMR vaccine or a placebo.

82 with DTP vaccine, 137,457 vaccinations with MMR vaccine, or no recent vaccination.

83 Following introduction of a replacement MMR vaccine (Priorix; GlaxoSmithKline, London, United Ki

84 ears, and probably reflect the impact of the MMR vaccine programme and the use of more sensitive diag

85 The measles, mumps, and rubella (MMR) vaccine protects against all-cause mortality in chi

86 MMR vaccine receipt (0, 1, 2 doses) between birth and 5

87 ings indicate no harmful association between MMR vaccine receipt and ASD even among children already

88 MMR vaccine receipt was not associated with an increased

89 r second dose for the Measles-Mumps-Rubella (MMR) vaccine starting in 2026 in the United Kingdom.

90 immunized (2 doses of measles-mumps-rubella [MMR] vaccine) students and residents were tested; 305 of

91 e with or without the measles-mumps-rubella (MMR) vaccine, the MMR vaccine only, and the expanded 200

92 sceptible persons, and administration of the MMR vaccine to more than 10,000 persons.

93 icate that administration of TCVs and/or the MMR vaccine to rhesus macaques does not result in neurop

94 of measles outbreaks caused by reduction in MMR vaccine uptake.

95 ella vaccine and collectively referred to as MMR vaccine) uptake was monitored with the use of the Ci

96 sted relative risk (RR) of ASD for 1 dose of MMR vaccine vs no vaccine was 0.76 (95% CI, 0.49-1.18; P

97 Receipt of MMR vaccine was associated with an increased risk of feb

98 nd autism, including a study that found that MMR vaccine was not associated with an increased risk of

99 children with older siblings, receipt of the MMR vaccine was not associated with increased risk of AS

100 ttributable to the administration of DTP and MMR vaccines was estimated to be 6 to 9 and 25 to 34 per

101 fter receipt of measles, mumps, and rubella (MMR) vaccine were tested for the ability to neutralize a

102 ranting further development as a tetravalent MMR vaccine, which may include protection against SARS-C

103 wo doses of the measles, mumps, and rubella (MMR) vaccine, which contains genotype A mumps vaccine.

104 l, 97% had received at least one dose of the MMR vaccine, with 2.5% having personal-belief exemptions

105 were documented among those who received the MMR vaccine within 30 d pretransplant in real-world prac

106 (3) outcomes for recipients who received the MMR vaccine within 30 d pretransplant.